Form 4: IRADIMED CEO Sells 5,000 Shares Under 10b5-1 Plan

IRADIMED's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for $71.2581 per share under a pre-arranged trading plan.

Summary

• Roger E. Susi, CEO, President, and Chairman of IRADIMED CORP, reported the sale of 5,000 shares of common stock.
• The transaction occurred on September 23, 2025, at a weighted average price of $71.2581 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
• Following the transaction, Mr. Susi directly beneficially owns 2,352,500 shares of common stock.
• He also indirectly beneficially owns 162,950 shares through the Phillip Susi 2008 Dynasty Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust.

Sentiment

Score: 6

Explanation: The sale of shares by a key executive is generally viewed neutrally to slightly negatively. However, the execution under a Rule 10b5-1 plan mitigates potential negative interpretations, suggesting a pre-planned financial management decision rather than a reaction to adverse company news. The sale represents a small fraction of the executive's total beneficial ownership.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent events.
• The shares were sold at a relatively high weighted average price of $71.2581.

Negatives

• A reduction in direct beneficial ownership by a key executive, which can sometimes be perceived negatively by the market.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

This Form 4 filing, detailing an insider stock sale, is a routine disclosure required by the SEC and does not inherently provide information related to broader industry trends or competitor activities. It reflects an individual executive's personal financial planning.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for insider transactions and does not contain information that allows for a direct comparison to industry-specific operational or financial benchmarks. The transaction itself is a personal financial decision by an executive, not a corporate performance metric.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan suggests it's not based on new material non-public information. The reduction in direct ownership is minor relative to total holdings.

Next Steps

• Roger E. Susi undertakes to provide full information regarding the number of shares and prices of the transaction upon request to the SEC staff, the issuer, or a security holder.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider stock sale under a Rule 10b5-1 plan. While insider selling can sometimes be a negative signal, the pre-arranged nature of this transaction, coupled with the relatively small number of shares sold compared to the executive's total beneficial ownership, suggests it is a personal financial management decision rather than a reflection of a change in the company's fundamental outlook. The filing does not provide sufficient information to alter a fundamental investment thesis, thus a 'hold' recommendation is appropriate based solely on this document.

Keywords

IRADIMED CORP, IRMD, Roger E. Susi, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, 10% Owner